Concepedia

Feng Zhou

FZ

Statistics

Publications

43

Citations

2.1K

H-Index

29

Active since

1995

Affiliations

Indiana University – Purdue University Indianapolis(Current)

Indiana University School of Medicine

Wenzhou Medical University

First Affiliated Hospital of Wenzhou Medical University

Shanghai Medical College of Fudan University

Feng Zhou is an author at Indiana University – Purdue University Indianapolis specializing in medicine, oncology, and molecular oncology.

ORCID

Publications per year

1995–2023

43

Publications

43

Discovery of (<i>S</i>)-1-(1-(Imidazo[1,2-<i>a</i>]pyridin-6-yl)ethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

Hong Jia, Guangxiu Dai, Jianyang Weng et al. · Journal of Medicinal Chemistry · 2014 · 134 citations · Full text

, , +9

Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer

Shuai Gao, Sujun Chen, Dong Han et al. · Nature Genetics · 2020 · 124 citations · Full text

, , +14

Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer

Qing Dong, Douglas R. Dougan, Xianchang Gong et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 122 citations · Full text

, , +10

Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models

Paul R. Gavine, Yongxin Ren, Lu Han et al. · Molecular Oncology · 2014 · 121 citations · Full text

, , +17

Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir

Xiangrui Jiang, Haixia Su, Weijuan Shang et al. · Nature Communications · 2023 · 107 citations · Full text

, , +12

1–5 of 43